Search for a trial

PHARMACOKINETICS OF CARBOPLATIN AFTER ADJUSTED DOSING FOR HIGH BMI, LOW SERUM CREATININE, AND MAXIMAL RENAL FUNCTION

The primary objective of the study is to determine the mean prediction error (MPE) and mean absolute prediction error (MAPE) of the area under the plasma concentration-time curve (AUC) of carboplatin after adjusted dosing for high BMI (BMI &gt…

A single arm open label multicentre extension study of bevacizumab in patients with solid tumours on study treatment with bevacizumab at the end of a F. Hoffmann-La Roche and/or Genentech sponsored study.

To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…

A European multicenter open-label study of breakthrough cancer pain: assessment of fentanyl buccal tablets titration and treatment in opioid-tolerant patients.

The primary objective is to compare the percentage of patients reaching an effective FBT dose with a starting dose of 100 mcg to those with a starting dose of 200 mcg. Secondary objectives are to evaluate the safety and tolerability and the…

A pharmacokinetic evaluation of the addition of Aprepitant to the Cisplatin - Etoposide (CE) treatment of patients with metastatic lung carcinoma (ACE)

The question is whether aprepitant should be added to CE cycles (cisplatin containing regimen with etoposide) because of a possible interaction between aprepitant and etoposide.This question derives from the fact that both drugs are metabolised…

The Effect of Enzalutamide on Oxycodone Metabolism in Men with Prostate Cancer

To investigate the effect of enzalutamide on the pharmacokinetics (PK) of oxycodone following a single 15 mg oral dose of normal-release oxycodone in men with prostate cancer.

Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.

The primary objective of this study is to evaluate the patient preference for either ICI-B or ICI-P. Secondary objectives are: to assess patient satisfaction with ICI-B and ICI-P, to establish the safety of ICI-B and ICI-P to establish the…

The nephroprotective effect of short hydration during cisplatin treatment in head and neck cancer patients.

To evaluate the incidence of CIN during cisplatin 40mg/m2 Q1W chemotherapy in patients with head and neck cancer and establish whether SH is superior to LH during cisplatin chemotherapy in reducing the incidence of AKI grade>=1.Secondary…

CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy

To demonstrate that a dose reduction of 20-33% of CYP3A4 metabolized tyrosine kinase inhibitors in patients expressing the CYP3A4*22 gene (rs35599367 C>T in intron 6) does not result in a lower exposure (Ctrough) than the wildtype group with…